




Securing the collaboration between industry and healthcare professionals


Collaboration between industry, healthcare professionals (HCPs) and healthcare organisations (HCOs) delivers better outcomes for patients. These partnerships have led to **major advances in care** – helping to prevent disease, improve diagnosis, and transform treatment options across Europe.



HIV, once a death sentence in the 1980s, is now considered a chronic condition that **can be managed long-term** with the right treatment.



98% of patients living with Hepatitis C can now be cured through an 8-12 week course of medicines.



Almost 100% of cervical cancer cases, a major cause of mortality among women just a few years ago, **can now be prevented** thanks to the HPV vaccine.

Industry and HCPs collaborate on a range of activities – from clinical trials and scientific exchange to best clinical practice and how new medicines fit into the patient pathway. EFPIA believes HCPs should be **fairly compensated for the expertise, time and services** they provide to the industry.

At a time of rising public expectations around openness, it is more important than ever that these vital collaborations are **transparent, clearly communicated, and well understood**. The relationship is already governed by strict rules, but greater transparency supports public trust and helps demonstrate how these interactions ultimately benefit patients and society.

That's why, since June 2016, **EFPIA member companies have publicly disclosed transfers of value** made to HCPs and HCOs – including consultancy work, advisory roles, speaker fees, and support to attend medical congresses. This step has been a defining moment for how the pharmaceutical industry interacts with the healthcare community, and it is a result of the EFPIA Disclosure Requirements.




About the Disclosure provisions in the EFPIA Code

The Disclosure provisions require all EFPIA member companies – and companies that are part of EFPIA member associations – to **disclose transfers of value to HCPs and HCOs**. This includes disclosing the name of the individual HCP or organisation receiving support and the total amount transferred, broken down by type of activity. These could consist of, for instance, a grant to an HCO, a consultancy fee for speaking, payment for travel, or registration fees for medical conferences.

This information is published annually on a **publicly accessible platform** – either on individual company websites or, in some countries, on a national centralised portal that consolidates data from across the industry. The goal is to make it easy for stakeholders and the public to **access consistent, clear information** about these interactions.

Why was the EFPIA Disclosure created?

Collaborative working between HCPs and life sciences companies has long been a **positive driver for advancements in patient care and the progression of innovative medicine**. HCPs offer unique insights based on their daily interactions with patients. Their expertise is critical to identifying unmet needs, understanding real-world treatment experiences, and helping bring forward the most relevant innovations. Similarly, industry brings deep scientific and technological capabilities that support the discovery and development of new medicines. This partnership has never been more important – but neither has the need to make it more visible. The EFPIA Disclosure initiative was created to **protect the integrity of these interactions, promote responsible collaboration, and reinforce public trust** in how healthcare decisions are made. It is part of EFPIA's broader commitment to transparency, responsibility and sustainability across the pharmaceutical ecosystem.



Who needs to comply with the EFPIA Disclosure Requirements?

The EFPIA Code applies to **all EFPIA members**, including member companies, members of EFPIA's specialised group Vaccines Europe (VE), and companies that are members of national trade associations represented within EFPIA, even if they are not direct EFPIA members. This includes most major pharmaceutical companies operating across Europe. A full list of EFPIA Member Companies, Member Associations, and the countries in which they operate is available at: www.efpia.eu/about-us/membership.

Where do I find out more information?

You can access more information at www.efpia.eu/relationships-code/